[go: up one dir, main page]

WO2004013629A3 - Screening for agents suitable for treatment of leukocyte associated inflammatory diseases - Google Patents

Screening for agents suitable for treatment of leukocyte associated inflammatory diseases Download PDF

Info

Publication number
WO2004013629A3
WO2004013629A3 PCT/EP2003/008313 EP0308313W WO2004013629A3 WO 2004013629 A3 WO2004013629 A3 WO 2004013629A3 EP 0308313 W EP0308313 W EP 0308313W WO 2004013629 A3 WO2004013629 A3 WO 2004013629A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
screening
treatment
agents suitable
associated inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008313
Other languages
French (fr)
Other versions
WO2004013629A2 (en
Inventor
Sau Wei Li
Christopher Terence Poll
John Westwick
Martin Gosling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0217503.2A external-priority patent/GB0217503D0/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to JP2004525342A priority Critical patent/JP2005534311A/en
Priority to AU2003251650A priority patent/AU2003251650A1/en
Priority to EP03766324A priority patent/EP1527343A2/en
Publication of WO2004013629A2 publication Critical patent/WO2004013629A2/en
Publication of WO2004013629A3 publication Critical patent/WO2004013629A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to an assay for substances that modulate the activity of a polypeptide encoded human transient receptor potential 6 gene (TRPC6). The assay involves combining a candidate substrate substance with the polypeptide and measuring the effect of the candidate substance on the activity of said polypeptide. Such substances may be used in the preparation of pharmaceuticals for treating inflammatory diseases, particularly those associated with leukocytes.
PCT/EP2003/008313 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases Ceased WO2004013629A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004525342A JP2005534311A (en) 2002-07-29 2003-07-28 Screening for suitable agents for the treatment of leukocyte-related inflammatory diseases
AU2003251650A AU2003251650A1 (en) 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
EP03766324A EP1527343A2 (en) 2002-07-29 2003-07-28 Organic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0217503.2A GB0217503D0 (en) 2002-07-29 2002-07-29 Organic compounds
GB0217503.2 2002-07-29
US41512402P 2002-09-30 2002-09-30
US60/415,124 2002-09-30

Publications (2)

Publication Number Publication Date
WO2004013629A2 WO2004013629A2 (en) 2004-02-12
WO2004013629A3 true WO2004013629A3 (en) 2004-05-06

Family

ID=31497250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008313 Ceased WO2004013629A2 (en) 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases

Country Status (4)

Country Link
EP (1) EP1527343A2 (en)
JP (1) JP2005534311A (en)
AU (1) AU2003251650A1 (en)
WO (1) WO2004013629A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526905A (en) * 2005-01-12 2008-07-24 サノフィ−アベンティス Use of TRPC channels to treat cardiovascular disease
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
KR100953821B1 (en) * 2007-12-03 2010-04-21 순천향대학교 산학협력단 Asthma Diagnostic Markers and Asthma Therapeutics Using Vitamin D-binding Protein
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
WO2014117680A2 (en) * 2013-02-04 2014-08-07 中国科学院上海生命科学研究院 Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025063A1 (en) * 1996-01-11 1997-07-17 The Wellesley Hospital Foundation Compositions including calcium influx blockers for inhibiting cell growth
WO2000004929A1 (en) * 1998-07-24 2000-02-03 South Alabama Medical Science Foundation Use of decreasing levels of functional transient receptor potential gene product
WO2002048342A2 (en) * 2000-12-11 2002-06-20 Deltagen, Inc. Knockout mice for trp6 gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025063A1 (en) * 1996-01-11 1997-07-17 The Wellesley Hospital Foundation Compositions including calcium influx blockers for inhibiting cell growth
WO2000004929A1 (en) * 1998-07-24 2000-02-03 South Alabama Medical Science Foundation Use of decreasing levels of functional transient receptor potential gene product
WO2002048342A2 (en) * 2000-12-11 2002-06-20 Deltagen, Inc. Knockout mice for trp6 gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAERSCH, G. ET AL: "Differential effects of two calcium channel blockers on bronchial smooth muscle", ARZNEIMITTEL-FORSCHUNG, vol. 45, no. 12, 1995, pages 1294 - 1297, XP008027738 *
CHUNG, S. ET AL: "Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 113, no. 3, 1994, pages 861 - 868, XP008027740 *
INOUE R. ET AL: "The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel", CIRCULATION RESEARCH, vol. 88, no. 3, 2001, pages 325 - 332, XP002220260, ISSN: 0009-7330 *
TIRUPPATHI C ET AL: "IMPAIRMENT OF STORE-OPERATED CA2+ ENTRY IN TRPC4-/- MICE INTERFERES WITH INCREASE IN LUNG MICROVASCULAR PERMEABILITY", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 91, no. 1, July 2002 (2002-07-01), pages 70 - 76, XP008010300, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
AU2003251650A1 (en) 2004-02-23
EP1527343A2 (en) 2005-05-04
WO2004013629A2 (en) 2004-02-12
JP2005534311A (en) 2005-11-17
AU2003251650A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
BR0315688A (en) Compounds, pharmaceutical compositions and their uses in the treatment or prevention of diseases or conditions of metabolic cell proliferation
AU2003212729A8 (en) Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
WO2003000853A3 (en) Protein aggregation assays and uses thereof
DE60232660D1 (en) HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS
WO2004044168A8 (en) Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
EP2402372A3 (en) Therapeutic agent
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
WO2004013629A3 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
EP1589115A3 (en) Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
ATE385517T1 (en) INTERFERON-LIKE MOLECULES AND USES THEREOF
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2005041631A3 (en) Endotheliase-1 ligands
PT723552E (en) OLIGOPEPTIDES DERIVED FROM REAGENT PROTEIN FRAGMENTS
ATE447027T1 (en) BACTERIAL PHEROMONES AND THEIR USES
WO2005082398A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
WO2003072606A3 (en) Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
Kongthong et al. Effect of narrowband ultraviolet B therapy on serum levels of CD26/dipeptidyl-peptidase IV and truncated forms of substance P in psoriasis patients with pruritus
WO1999049037A3 (en) Protein phosphatase-related molecules
WO2006063009A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
Miller et al. Inhibition of neurotensin-stimulated mast cell secretion and carboxypeptidase A activity by the peptide inhibitor of carboxypeptidase A and neurotensin-receptor antagonist SR 48692
ATE554393T1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ADIPONECTIN RECEPTOR 2 (ADIPOR2).
AU2002247655A1 (en) Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003766324

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004525342

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003766324

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003766324

Country of ref document: EP